Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis

Conclusions: Sorafenib combined with regional therapies may be associated with prolonged OS and TTP in HCC patients with pulmonary oligometastases compared with sorafenib monotherapy.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Jinbin Chen, Shixun Lu, Yaojun Zhang, Li Xu, Jiancong Chen, Juncheng Wang, Minshan Chen, Rongxin Zhang, Zhongguo Zhou Tags: Research Paper Source Type: research